Evidence of response to pembrolizumab in a patient with Lynch syndrome-related metastatic colon cancer.

Abstract:

:Patients with Lynch Syndrome (LS) are at high risk of developing colorectal cancer at an early age. Germline mutations in DNA mismatch repair genes and microsatellite instability are clear signatures of this autosomal dominant disorder. Here, we report the clinical history of a 38-year-old patient with LS-related metastatic colon cancer treated in Chile with immunotherapy (pembrolizumab). The patient exhibited a pathogenic deletion in Epithelial cell Adhesion Molecule (EPCAM) and mutS homolog 2 (MSH2) genes, and after diagnosis received 12 cycles of FOLFOX. The tumor mass, however, continued to grow, and a new metastatic mucinous adenocarcinoma of 13 mm appeared at the level of the 11th right dorsal vertebra. To treat these lesions, the patient received immunotherapy scheme with pembrolizumab (200 mg every 21 days). After only four cycles, the patient's symptoms improved and the lesions showed less metabolic activity. After 12 cycles with pembrolizumab, the patient started palliative radiation and systemic second-line treatment with FOLFIRI and Avastin. The immunotherapy scheme with pembrolizumab was capable of delaying the second-line treatment for at least 8 months, becoming a useful therapeutic option for this patient. Thus, our study highlights the importance of implementing immunotherapy treatment programs for LS-colorectal cancer patients in South American countries.

journal_name

Onco Targets Ther

journal_title

OncoTargets and therapy

authors

Salman P,Panay S,Fernández R,Mahave M,Soza-Ried C

doi

10.2147/OTT.S167645

subject

Has Abstract

pub_date

2018-10-23 00:00:00

pages

7295-7300

issn

1178-6930

pii

ott-11-7295

journal_volume

11

pub_type

  • p53 inhibits the expression of p125 and the methylation of POLD1 gene promoter by downregulating the Sp1-induced DNMT1 activities in breast cancer.

    abstract::p125 is one of four subunits of human DNA polymerases - DNA Pol δ as well as one of p53 target protein encoded by POLD1. However, the function and significance of p125 and the role that p53 plays in regulating p125 expression are not fully understood in breast cancer. Tissue sections of human breast cancer obtained fr...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S98713

    authors: Zhang L,Yang W,Zhu X,Wei C

    更新日期:2016-03-10 00:00:00

  • Targeted therapy in the treatment of malignant gliomas.

    abstract::Malignant gliomas are invasive tumors with the potential to progress through current available therapies. These tumors are characterized by a number of abnormalities in molecular signaling that play roles in tumorigenesis, spread, and survival. These pathways are being actively investigated in both the pre-clinical an...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/ott.s3027

    authors: Lukas RV,Boire A,Nicholas MK

    更新日期:2009-02-18 00:00:00

  • Targeted therapies in the management of colorectal carcinoma: role of bevacizumab.

    abstract::Colorectal cancer continues to be an important public health concern, despite improvements in screening and better systemic chemotherapy. The integration of targeted therapies in the treatment of colon cancer has resulted in significant improvements in efficacy outcomes. Angiogenesis is important for tumor growth and ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:

    authors: Puthillath A,Patel A,Fakih MG

    更新日期:2009-02-18 00:00:00

  • Leucine-rich glioma inactivated 3: integrative analyses support its prognostic role in glioma.

    abstract:BACKGROUND:Leucine-rich glioma inactivated 3 (LGI3) is a secreted protein member of LGI family. We previously reported that LGI3 was expressed in brain, adipose tissues and skin, where it played roles as a multifunctional cytokine. We postulated that LGI3 may be involved in cytokine network in cancers. AIM:This study ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S138912

    authors: Kwon NS,Kim DS,Yun HY

    更新日期:2017-05-24 00:00:00

  • MiR-503 inhibits hepatocellular carcinoma cell growth via inhibition of insulin-like growth factor 1 receptor.

    abstract::MicroRNAs (miRs) have been demonstrated to play key roles in the development and progression of hepatocellular carcinoma (HCC). However, the regulatory mechanism of miR-503 in HCC has not been fully uncovered. In this study, we found that miR-503 was significantly downregulated in HCC tissues compared to nontumorous l...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S106351

    authors: Xiao Y,Tian Q,He J,Huang M,Yang C,Gong L

    更新日期:2016-06-15 00:00:00

  • Primary Diffuse Large B-Cell Lymphoma of the Female Urethra: A Case Report and Review of the Literature.

    abstract::Primary urethral non-Hodgkin's lymphoma (NHL) is uncommon. This case study reports the case of a 52-year-old woman with a light red mass at the urethral orifice. Her clinical manifestations included frequent urination, urgency, dysuria, and occasionally blood in urine. The tumor was surgically removed, and the patholo...

    journal_title:OncoTargets and therapy

    pub_type:

    doi:10.2147/OTT.S283704

    authors: Zeng H,Wang J,Deng R,Chen Z

    更新日期:2020-12-21 00:00:00

  • CXCL12 genetic variants as prognostic markers in nasopharyngeal carcinoma.

    abstract::The chemokine receptor 4/chemokine ligand 12 (CXCR4/CXCL12) axis plays an important role in tumorigenesis, metastasis, and recurrence of tumors. Its single nucleotide polymorphisms (SNPs) are associated with patient survival in several types of cancer. However, the prognostic value of SNPs in nasopharyngeal carcinoma ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S90430

    authors: Chen R,Xu Y,Du X,Liu N,Li Y,He Q,Tang L,Mao Y,Sun Y,Chen L,Ma J

    更新日期:2015-10-08 00:00:00

  • Erratum: IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Corrigendum].

    abstract::[This corrects the article DOI: 10.2147/OTT.S262089.]. ...

    journal_title:OncoTargets and therapy

    pub_type: 已发布勘误

    doi:10.2147/OTT.S292577

    authors:

    更新日期:2020-11-27 00:00:00

  • MFAP2 promotes epithelial-mesenchymal transition in gastric cancer cells by activating TGF-β/SMAD2/3 signaling pathway.

    abstract:Introduction:Microfibril-associated protein 2 (MFAP2) is an extracellular matrix protein that interacts with fibrillin to modulate the function of microfibrils. MFAP2 has been reported to play a significant role in obesity, diabetes, and osteopenia, and has been shown to be upregulated in head and neck squamous cell ca...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S160831

    authors: Wang JK,Wang WJ,Cai HY,Du BB,Mai P,Zhang LJ,Ma W,Hu YG,Feng SF,Miao GY

    更新日期:2018-07-12 00:00:00

  • Forkhead Box S1 Inhibits the Progression of Hepatocellular Carcinoma.

    abstract:Introduction:Forkhead box (FOX) superfamily members were recently shown to play important roles in tumor development and progression. Forkhead box S1 (FOXS1), a member of the FOX family, has been reported to be closely associated with malignant neoplasms. However, its expression and effect on hepatocellular carcinoma r...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S272596

    authors: Lei D,Hu G,Chen Y,Hao T,Gao Y,Luo F

    更新日期:2020-11-17 00:00:00

  • Genetic ablation of TAZ induces HepG2 liver cancer cell apoptosis through activating the CaMKII/MIEF1 signaling pathway.

    abstract:Background and objective:Transcriptional coactivator with PDZ-binding motif (TAZ) has been found to be associated with tumor progression. Mitochondrial homeostasis regulates cancer cell viability and metastasis. However, the roles of TAZ and mitochondrial homeostasis in liver cancer viability have not been explored. Th...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S196142

    authors: Hou Y,Lan C,Kong Y,Zhu C,Peng W,Huang Z,Zhang C

    更新日期:2019-03-01 00:00:00

  • Coincident primary breast lymphoma and gastrointestinal stromal tumor: case series and molecular mechanisms.

    abstract::Gastrointestinal stromal tumor (GIST) is an uncommon mesenchymal tumor, and has been shown to be associated with synchronous or metachronous second malignancies. Rare cases of coincident GIST and non-Hodgkin lymphomas (NHL) have been reported previously. Here, we report two cases of GIST and coincident primary breast ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S159843

    authors: Ludmir EB,Gutschenritter T,Pinnix CC,Gunther JR,Nastoupil LJ,Khoury JD,Medeiros LJ,Dabaja BS,Milgrom SA

    更新日期:2018-12-10 00:00:00

  • Exploring targeted therapy of osteosarcoma using proteomics data.

    abstract::Despite multimodal therapeutic treatments of osteosarcoma (OS), some patients develop resistance to currently available regimens and eventually end up with recurrent or metastatic outcomes. Many attempts have been made to discover effective drugs for improving outcome; however, due to the heterogeneity of the disease,...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S119993

    authors: Chaiyawat P,Settakorn J,Sangsin A,Teeyakasem P,Klangjorhor J,Soongkhaw A,Pruksakorn D

    更新日期:2017-02-01 00:00:00

  • Mapping lymph nodes in cancer management - role of (99m)Tc-tilmanocept injection.

    abstract::Two decades ago, lymphatic mapping of sentinel lymph nodes (SLN) was introduced into surgical cancer management and was termed sentinel node navigated surgery. Although this technique is now routinely performed in the management of breast cancer and malignant melanoma, it is still under investigation for use in other ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S50394

    authors: Tausch C,Baege A,Rageth C

    更新日期:2014-06-24 00:00:00

  • Identification of novel biomarkers and candidate small molecule drugs in non-small-cell lung cancer by integrated microarray analysis.

    abstract::Background: Non-small-cell lung cancer (NSCLC) remains the leading cause of cancer morbidity and mortality worldwide. In the present study, we identified novel biomarkers associated with the pathogenesis of NSCLC aiming to provide new diagnostic and therapeutic approaches for NSCLC. Methods: The microarray datasets of...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S198621

    authors: Wu Q,Zhang B,Sun Y,Xu R,Hu X,Ren S,Ma Q,Chen C,Shu J,Qi F,He T,Wang W,Wang Z

    更新日期:2019-05-13 00:00:00

  • The Acetone Indigo Red Dehydrating Agent IF203 Induces HepG2 Cell Death Through Cell Cycle Arrest, Autophagy and Apoptosis [Retraction].

    abstract::[This retracts the article DOI: 10.2147/OTT.S232594.]. ...

    journal_title:OncoTargets and therapy

    pub_type: 撤回出版物

    doi:10.2147/OTT.S283590

    authors:

    更新日期:2020-10-07 00:00:00

  • Long Non-Coding RNA 691 Regulated PTEN/PI3K/AKT Signaling Pathway in Osteosarcoma Through miRNA-9-5p.

    abstract:Background:Large amounts of researches indicate that non-coding RNAs play a crucial role in many malignancies. However, the potential mechanisms of non-coding RNAs involved in osteosarcoma tumorigenesis remain elusive. Materials and Methods:The expression of long non-protein coding RNA 691 (lncRNA 691) in cell lines a...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S249827

    authors: Yao P,Ni Y,Liu C

    更新日期:2020-05-22 00:00:00

  • Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives.

    abstract::Discovered in 2007, anaplastic lymphoma kinase (ALK) gene rearrangements positive (ALK+) lung cancers compose a small subset of non-small cell lung cancer (NSCLC), with rapidly expanded treatments. There are currently several ALK inhibitors, including crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib which ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S174548

    authors: Karachaliou N,Fernandez Bruno M,Bracht JWP,Rosell R

    更新日期:2019-06-13 00:00:00

  • MicroRNA-559 plays an inhibitory role in the malignant progression of glioblastoma cells by directly targeting metadherin.

    abstract::Purpose: Several microRNAs (miRNAs) that are aberrantly expressed in glioblastoma multiforme (GBM) play a significant role in GBM formation and progression. The expression profile and functions of miR-559 in GBM remain unclear. Here, we quantified the expression and investigated the involvement of miR-559 in the oncog...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S202309

    authors: Yang F,Zhang C,Xu C,Fu F,Han D,Li H

    更新日期:2019-06-05 00:00:00

  • Metformin induces apoptosis of human hepatocellular carcinoma HepG2 cells by activating an AMPK/p53/miR-23a/FOXA1 pathway.

    abstract::The antidiabetic drug metformin has been shown to possess antitumor functions in many types of cancers. Although studies have revealed its beneficial effects on the prognosis of hepatocellular carcinoma (HCC), the detailed molecular mechanism underlying this event remains largely unknown. In this work, we showed that ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S99770

    authors: Sun Y,Tao C,Huang X,He H,Shi H,Zhang Q,Wu H

    更新日期:2016-05-12 00:00:00

  • Comparison of short-term outcomes between minimally invasive McKeown and Ivor Lewis esophagectomy for esophageal or junctional cancer: a systematic review and meta-analysis.

    abstract:Purpose:Minimally invasive esophagectomy is increasingly performed for esophageal or gastroesophageal junctional cancer, with advantages of improved perioperative outcomes in comparison with open esophagectomy. McKeown and Ivor Lewis are widely used procedures of minimally invasive esophagectomy, and there have been co...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S169488

    authors: Deng J,Su Q,Ren Z,Wen J,Xue Z,Zhang L,Chu X

    更新日期:2018-09-20 00:00:00

  • Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib.

    abstract::Over the last decades, a better understanding of breast cancer heterogeneity provided tools for a biologically based personalization of anticancer treatments. In particular, the overexpression of the human epidermal growth factor receptor 2 (HER2) by tumor cells provided a specific target in these HER2-positive tumors...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S122397

    authors: Kourie HR,El Rassy E,Clatot F,de Azambuja E,Lambertini M

    更新日期:2017-07-10 00:00:00

  • Ocular basal cell carcinoma: a brief literature review of clinical diagnosis and treatment.

    abstract::Basal cell carcinoma (BCC) is a common malignant tumor throughout the world. One of the known risk factors of BCC is intense exposure to ultraviolet radiation. More than 50% of BCCs of the eyelid initially occur on the lower lid. The gold standard of diagnosis of BCC is histopathology. Treatment options for BCC consis...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S130371

    authors: Shi Y,Jia R,Fan X

    更新日期:2017-05-08 00:00:00

  • Molecular profiling in the treatment of colorectal cancer: focus on regorafenib.

    abstract::Metastatic colorectal cancer (mCRC) is a highly heterogeneous disease. Its treatment outcome has been significantly improved over the last decade with the incorporation of biological targeted therapies, including anti-EGFR antibodies, cetuximab and panitumumab, and VEGF inhibitors, bevacizumab, ramucirumab, and aflibe...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S79145

    authors: Yan Y,Grothey A

    更新日期:2015-10-15 00:00:00

  • FAM111B, a direct target of p53, promotes the malignant process of lung adenocarcinoma.

    abstract::Purpose: Lung adenocarcinoma (LUAD) is a main subtype of lung cancer, which is the leading cause of cancer-related deaths. The five-year survival rates of lung cancer patients are still comparatively low. Therefore, potential therapeutic targets are urgently needed to improve the survival of lung cancer patients. In t...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S190934

    authors: Sun H,Liu K,Huang J,Sun Q,Shao C,Luo J,Xu L,Shen Y,Ren B

    更新日期:2019-04-17 00:00:00

  • Tooth loss and risk of colorectal cancer: a dose-response meta-analysis of prospective cohort studies.

    abstract:Background:Previous studies have indicated that tooth loss is associated with colorectal cancer risk but have presented controversial results. Methods:We conducted a dose-response meta-analysis in order to investigate the correlation between tooth loss and colorectal cancer risk. Up to August 2017, six eligible studie...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S151028

    authors: Ma P,Dai S,Jin C,Yao Y,Zou C

    更新日期:2018-03-21 00:00:00

  • Atypical aleukemic presentation of large granular lymphocytic leukemia: a case report.

    abstract::Large granular lymphocytic leukemia (LGLL) is a rare lymphoproliferative disorder of transformed natural killer or T-cells attributed to chronic exposure to the proinflammatory cytokine IL-15. Diagnosis of the majority of T-cell LGLL is established by documenting clonal large granular lymphocytes (LGLs) in peripheral ...

    journal_title:OncoTargets and therapy

    pub_type:

    doi:10.2147/OTT.S115892

    authors: Bagacean C,Tempescul A,Patiu M,Fetica B,Bumbea H,Zdrenghea M

    更新日期:2016-12-19 00:00:00

  • Coexisting of COX7A2L-ALK, LINC01210-ALK, ATP13A4-ALK and Acquired SLCO2A1-ALK in a Lung Adenocarcinoma with Rearrangements Loss During the Treatment of Crizotinib and Ceritinib: A Case Report.

    abstract::ALK rearrangements account for ~5% of non-small-cell lung cancer (NSCLC). Numerous rearrangement partners have been discovered. Here, we describe a 53-year-old nonsmoker with NSCLC, in whom we identified four novel rearrangements. The patient was diagnosed as adenocarcinoma in the right middle lobe of lung, with metas...

    journal_title:OncoTargets and therapy

    pub_type:

    doi:10.2147/OTT.S258067

    authors: Cai C,Long Y,Li Y,Huang M

    更新日期:2020-08-20 00:00:00

  • Celastrol induces ubiquitin-dependent degradation of mTOR in breast cancer cells.

    abstract:Background:Celastrol is a major active component of the thunder god vine (Tripterygium wilfordii) used in traditional Chinese medicine to treat chronic inflammatory and autoimmune diseases. Celastrol inhibits PI3K-Akt-mTOR signaling, which is frequently dysregulated in tumors and critical for tumor-cell proliferation a...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S187315

    authors: Li X,Zhu G,Yao X,Wang N,Hu R,Kong Q,Zhou D,Long L,Cai J,Zhou W

    更新日期:2018-12-11 00:00:00

  • Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice.

    abstract:Background:Several trials evaluated the role of intensive regimens, made of triplet chemotherapies plus bevacizumab, as first-line treatment for patients with metastatic colorectal cancer (mCRC). We previously reported, in a Phase II prospective study, the efficacy and the tolerability of FIrB/FOx regimen, reporting in...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S194745

    authors: Cortellini A,Cannita K,Parisi A,Lanfiuti Baldi P,Venditti O,D'Orazio C,Dal Mas A,Calvisi G,Giordano AV,Vicentini V,Vicentini R,Felicioni L,Marchetti A,Buttitta F,Russo A,Ficorella C

    更新日期:2019-03-25 00:00:00